Dover has entered into a definitive agreement to accumulate Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and control devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s merchandise will expand Dover’s biopharma single-use production providing, which already includes Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with facilities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in revenue through the full yr 2022.
When Banned closes, Malema will turn into a part of the PSG business unit inside Dover’s Pumps & Process Solutions phase.
“We see a tremendous long-term progress opportunity within the bioprocessing trade driven by a powerful and rising pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of extra efficient single-use production processes supports a robust outlook for our choices of single-use components to end-customers. Manageable imagine that pairing Malema’s technology with our existing portfolio of single-use pumps for biopharma processing will significantly enhance the accuracy and value proposition of our solutions to our prospects.”
“We are methodically constructing out our biopharma platform through proactive capability additions, new product growth, and opportunistic acquisitions of highly-attractive niche part applied sciences,” mentioned Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing technology and further strengthens our sensor portfolio with new proprietary technology. In addition to enticing biopharma purposes, we count on sturdy progress in the semiconductor house on the capacity growth and re-shoring tailwinds.”
Share